{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T05:27:52Z","timestamp":1738819672742,"version":"3.37.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[1999,3,1]],"date-time":"1999-03-01T00:00:00Z","timestamp":920246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[1999,3,1]],"date-time":"1999-03-01T00:00:00Z","timestamp":920246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[1999,3]]},"DOI":"10.1136\/ard.58.3.182","type":"journal-article","created":{"date-parts":[[2008,12,6]],"date-time":"2008-12-06T00:32:33Z","timestamp":1228523553000},"page":"182-185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["CYP2C19 genotype does not represent a genetic predisposition in idiopathic systemic lupus erythematosus"],"prefix":"10.1016","volume":"58","author":[{"given":"Selim","family":"Kortunay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atila","family":"Bozkurt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lise","family":"Bathum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nursabah E","family":"Basci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meral","family":"\u00c7alg\u00fcneri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Br\u00f8sen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S O\u1e21uz","family":"Kayaalp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ard.58.3.182_bib1","first-page":"746","article-title":"Biology of disease: new concepts in the pathogenesis of drug-induced lupus","volume":"73","author":"Young","year":"1995","journal-title":"Lab Invest"},{"key":"10.1136\/ard.58.3.182_bib2","doi-asserted-by":"crossref","first-page":"118","DOI":"10.2165\/00003088-198106020-00003","article-title":"Acetylator phenotype and lupus erythematosus","volume":"6","author":"Uetrecht","year":"1981","journal-title":"Clin Pharmacokinet"},{"key":"10.1136\/ard.58.3.182_bib3","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/BF00316090","article-title":"Hydroxylation polymorphism of debrisoquine and mephenytoin in European populations","volume":"39","author":"Alvan","year":"1990","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1136\/ard.58.3.182_bib4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2125.1993.tb04204.x","article-title":"Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark","volume":"36","author":"Brosen","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"10.1136\/ard.58.3.182_bib5","first-page":"753","article-title":"Pharmacogenetics of mephenytoin, a new drug hydroxylation polymorphism in man","volume":"26","author":"K\u00fcpfer","year":"1984","journal-title":"Eur J Pharmacol"},{"key":"10.1136\/ard.58.3.182_bib6","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/clpt.1993.77","article-title":"Why are diazepam metabolism and polymorphic S-mephenytoin hydroxylation associated with each other in white and Korean populations but not in Chinese populations?","volume":"53","author":"Bertilsson","year":"1993","journal-title":"Clin Pharmacol Ther"},{"key":"10.1136\/ard.58.3.182_bib7","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1365-2125.1991.tb05594.x","article-title":"The activation of the biguanid antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism- a panel study","volume":"31","author":"Ward","year":"1991","journal-title":"Br J Clin Pharmacol"},{"key":"10.1136\/ard.58.3.182_bib8","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/0009-9236(95)90229-5","article-title":"The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: A population study","volume":"57","author":"Balain","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"10.1136\/ard.58.3.182_bib9","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/00008571-199512000-00004","article-title":"Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype","volume":"5","author":"Chang","year":"1995","journal-title":"Pharmacogenetics"},{"key":"10.1136\/ard.58.3.182_bib10","doi-asserted-by":"crossref","first-page":"15419","DOI":"10.1016\/S0021-9258(17)40694-6","article-title":"The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans","volume":"22","author":"deMorais","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1136\/ard.58.3.182_bib11","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0026-895X(25)09788-3","article-title":"Identification of a new genetic defect for the polymorphism of (S)-mephenytoin metabolism in Japanese","volume":"46","author":"deMorais","year":"1994","journal-title":"Mol Pharmacol"},{"key":"10.1136\/ard.58.3.182_bib12","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/S0022-3565(24)36606-6","article-title":"Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele","volume":"281","author":"Xiao","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1136\/ard.58.3.182_bib13","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/00008571-199510000-00007","article-title":"A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype","volume":"5","author":"Br\u00f8sen","year":"1995","journal-title":"Pharmacogenetics"},{"key":"10.1136\/ard.58.3.182_bib14","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/art.1780290705","article-title":"Altered distribution of debrisoquine oxidation phenotypes in patients with systemic lupus erythematosus","volume":"29","author":"Baer","year":"1986","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.58.3.182_bib15","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1136\/ard.55.1.66","article-title":"Relationship between genotype for the cytochrome P450 CYP2D6 and susceptibility to ankylosing spondylitis and rheumatoid arthritis","volume":"55","author":"Beyeler","year":"1996","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.58.3.182_bib16","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/clpt.1990.151","article-title":"Scleroderma is associated with differences in individual routes of drug metabolism: A study with dapsone, debrisoquine, and mephenytoin","volume":"48","author":"May","year":"1990","journal-title":"Clin Pharmacol Ther"},{"key":"10.1136\/ard.58.3.182_bib17","first-page":"1034","article-title":"Phenotype\/genotype relationships for the cytochrome P450 CYP2D6 in rheumatoid arthritis: influence of drug therapy and disease activity","volume":"21","author":"Beyeler","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.58.3.182_bib18","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/art.1780221106","article-title":"Alterations of estrogen metabolism in systemic lupus erythematosus","volume":"22","author":"Lahita","year":"1979","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.58.3.182_bib19","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1210\/jcem-53-1-174","article-title":"Increased 16-\u03b1-hydroxylation of estradiol in systemic lupus erythematosus","volume":"53","author":"Lahita","year":"1981","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1136\/ard.58.3.182_bib20","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1002\/art.1780261215","article-title":"Increased oxidation of testosterone in systemic lupus erythematosus","volume":"26","author":"Lahita","year":"1983","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.58.3.182_bib21","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/clpt.1982.147","article-title":"Microsomal hydroxylation as measured by pentobarbital elimination in patients with idiopathic systemic lupus erythematosus","volume":"32","author":"Drayer","year":"1982","journal-title":"Clin Pharmacol Ther"},{"key":"10.1136\/ard.58.3.182_bib22","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/art.1780251101","article-title":"The 1982 revised criteria for the classification of systemic lupus erythematosus","volume":"25","author":"Tan","year":"1982","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.58.3.182_bib23","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/clpt.1989.63","article-title":"S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquine","volume":"45","author":"Sanz","year":"1989","journal-title":"Clin Pharmacol Ther"},{"key":"10.1136\/ard.58.3.182_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00007691-199802000-00001","article-title":"A dual label oligonucleotide ligation assay for detection of the CYP2C19*1, CYP2C19*2 and CYP2C19*3 allele involving time resolved fluorometry","volume":"20","author":"Bathum","year":"1998","journal-title":"Ther Drug Monit"},{"key":"10.1136\/ard.58.3.182_bib25","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1365-2125.1994.tb04383.x","article-title":"S-mephenytoin, sparteine and debrisoquine oxidation: genetic polymorphism in a Turkish population","volume":"38","author":"Basci","year":"1994","journal-title":"Br J Clin Pharmacol"},{"key":"10.1136\/ard.58.3.182_bib26","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1046\/j.1365-2125.1996.00500.x","article-title":"Proguanil metabolism in relation to S-mephenytoin oxidation in a Turkish population","volume":"42","author":"Basci","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"10.1136\/ard.58.3.182_bib27","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s002280050373","article-title":"The hydroxylation of omeprazole correlates with S-mephenytoin and proguanil metabolism","volume":"53","author":"Kortunay","year":"1997","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1136\/ard.58.3.182_bib28","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1365-2125.1989.tb03426.x","article-title":"Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark","volume":"27","author":"Drohse","year":"1989","journal-title":"Br J Clin Pharmacol"},{"key":"10.1136\/ard.58.3.182_bib29","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/clpt.1994.154","article-title":"Pharmacogenetic characteristic of the eosinophilia-myalgia syndrome","volume":"56","author":"Flockhart","year":"1994","journal-title":"Clin Pharmacol Ther"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724436790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724436790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.58.3.182","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T18:34:39Z","timestamp":1738780479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724436790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,3]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1999,3]]}},"alternative-id":["S0003496724436790"],"URL":"https:\/\/doi.org\/10.1136\/ard.58.3.182","relation":{},"ISSN":["0003-4967"],"issn-type":[{"type":"print","value":"0003-4967"}],"subject":[],"published":{"date-parts":[[1999,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CYP2C19 genotype does not represent a genetic predisposition in idiopathic systemic lupus erythematosus","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.58.3.182","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 1999 Annals of the Rheumatic Diseases, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}